Bluebird Bio

Bluebird Bio

A company developing gene therapies for the treatment of genetic diseases and cancer.

Bluebird Bio, formerly Genetix Pharmaceuticals, is a biotechnology company developing multiple therapies for the treatment of genetic diseases and cancer that is headquartered in Cambridge, Massachusetts and was founded in 1993 by Philippe Leboulch. The company is developing gene addition therapies, gene editing therapies, and cancer immunotherapies for treating a variety of health conditions.

Funding

Series A

On June 17, 2004 Bluebird Bio completed their series A funding round with $8.5 million in funding from Nazem and Company and ABN AMRO Fund.

Venture round I

On October 7, 2004 Bluebird Bio completed a venture funding round with $12 million in funding from Techno Venture Management (lead investor), Easton Capital, and ABN AMRO Fund.

Series B

On March 12, 2010 Bluebird Bio completed their series B funding round with $35 million in funding from Third Rock Ventures (lead investor), Sanofi-Genzyme BioVentures (lead investor), TVM Capital, Forbion Capital Partners, and Easton Capital.

Grant

In 2011 Bluebird Bio received a grant worth $9.3 million from The California Institute of Regenerative Medicine (CIRM) to fund their Phase I/II study of LentiGlobin for the treatment of inherited betea-thalas-semia.

Venture round II

On April 20, 2011 Bluebird Bio completed their second venture funding round with $30 million in funding from ARCH Venture Partners (lead investor), Third Rock Ventures, Forbion Capital Partners, TVM Capital, and Easton Capital.

Series D

On July 25, 2012 Bluebird Bio completed their series D funding round with $60 million in funding from Third Rock Ventures, TVM Capital, Ramius Capital, RA Capital Management, Forbion Capital Partners, Deerfield Partners, and ARCH Venture Partners.

Post-IPO equity

On December 7, 2016 Bluebird Bio raised $250 million in post-IPO equity.

Timeline

July 25, 2012

Bluebird Bio raises a $60,000,000 series D round from Third Rock Ventures, ARCH Venture Partners and Forbion Capital Partners.

March 12, 2010

Bluebird Bio raises a $35,000,000 series B round from Third Rock Ventures and Forbion Capital Partners.

1993

Bluebird Bio was founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
3 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Akpeli Nordor

Employee

Amit Patel

Investor

Anne-Rachel Krostag

Employee

Charles R. Legg

Employee

Corey Bettencourt

Employee

Dawn Robinson

Employee

Jacob Ehrlich

Employee

Jason Yi

Employee

Jenny Severin

Employee

Marmi Le

Investor

Matthew Mackenzie

Employee

Megan Devine

Employee

Vanessa Belknap

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.